Cancer News and Research

Latest Cancer News and Research

Ontario Lung Association partners with Health Canada for radon gas awareness campaign

As winter weather approaches and we move activities indoors, it's a good time to think about the quality of the air in our homes. Radon is a colourless, odourless gas that is produced from the natural breakdown of uranium in rocks and soil. Radon can enter a home through tiny openings in floors and foundations and build up to dangerous levels. Long-term exposure to radon is the second leading cause of lung cancer in Canada.

26 Oct 2009

Results from Phase I dose-escalation study of AT-101 announced

Ascenta Therapeutics announced today that encouraging results from a Phase I dose-escalation study of two combination therapy regimens containing AT-101, an oral, pan-Bcl-2 inhibitor, in patients with the most malignant type of brain tumor, were described in an oral presentation at the 2009 Joint Meeting of the Society for NeuroOncology (SNO) and AANS/CNS Section on Tumors in New Orleans, Louisiana (Concurrent Session VI: Radiation Oncology, October 23, 2009; Abstract # 449).

26 Oct 2009

Rexahn Pharmaceuticals completes Registered Direct Offering of common stock and warrants

Rexahn Pharmaceuticals, Inc. announced today that it has completed its previously announced Registered Direct Offering of common stock and warrants. Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (NasdaqGM: RODM), acted as the exclusive placement agent for this transaction.

26 Oct 2009

Cel Sci completes its production facility for Multikine Phase III clinical trial

BioMedReports, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, was given an exclusive tour of CEL-SCI Corporation's, new, state-of-the-art manufacturing facility near Baltimore, MD where the potentially ground breaking cancer immunotherapy treatment, Multikine, will be manufactured to support an upcoming Phase III clinical trial.

26 Oct 2009

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

Antigenics today announced that the Brain Tumor Research Center at the University of California, San Francisco (UCSF), has presented an update on a Phase 2 clinical trial of Oncophage (vitespen) for recurrent high grade glioma (brain cancer) at the 2009 Joint Meeting of SNO (Society for Neuro-Oncology) and AANS/CNS Section on Tumors 2009 in New Orleans, LA.

26 Oct 2009

Overview of Compugen’s DAC Blockers Platform presented at Fifth Peptide Engineering Meeting

Speaking today in Barcelona at the Fifth Peptide Engineering Meeting, Compugen Ltd. project manager Dr. Yossef Kliger provided an overview of Compugen’s DAC Blockers Platform and reviewed disease model data for selected product candidates.

26 Oct 2009

SuperGen and GSK team up to discover and develop cancer therapeutics based on epigenetic targets

SuperGen, Inc. (NASDAQ:SUPG) and GlaxoSmithKline (NYSE:GSK) have entered into a multi-year collaboration to discover and develop cancer therapeutics based on epigenetic targets.

26 Oct 2009

Canadian cardiologists, oncologists team up to fight breast cancer

A team of Canadian cardiologists, in collaboration with oncologists, are playing an important role in the war against breast cancer Dr. Michael McDonald told the Canadian Cardiovascular Congress 2009, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

26 Oct 2009

Younger women experience larger improvements after myocardial infarction than men

In recent years, women, particularly younger women, experienced larger improvements in hospital mortality after myocardial infarction (MI) than men, according to a study published in the Oct. 26, 2009 issue of Archives of Internal Medicine.

26 Oct 2009

Japanese Patent granted for Pharmalink AB's Nefecon

Pharmalink AB announced today that it has been granted Japanese Patent No 4326696, "Methods and means for treating glomerulonephritis" for its product Nefecon(R) which is being developed to treat IgA nephropathy, a glomerulonephritis leading to end-stage renal disease (ESRD). Counterparts of the patent have been issued for other territories including the EU, US and China.

26 Oct 2009

Novel protein responsible for changing DNA structure and silencing the expression of genes identified

A study published recently in the Proceedings of the National Academy of Science (PNAS) by a team of scientists headed by Professors Hélène Bierne and Pascale Cossart from the Pasteur Institute, in collaboration with colleagues form the CNRS and the French Agricultural Research Institute (INRA), identified a novel protein, BAHD1, which is responsible for changing DNA structure and silencing the expression of genes.

26 Oct 2009

Potential link exists between histone mRNA formation and apoptosis

A study from the University of North Carolina at Chapel Hill has identified a key player in a molecular process essential for DNA replication within cells.

26 Oct 2009

USPTO reaffirms the validity of ExonHit Therapeutics' SpliceArray patent

ExonHit is pleased to announce that the United States Patent and Trademark Office (“USPTO”) notified the Company of its intent to issue a Re-examination Certificate in connection with ExonHit’s US Patent n° 6,881,571 directed to the use of its SpliceArray™ technology.

26 Oct 2009

New findings demonstrating pharmacoeconomic benefits of Ceplene released

EpiCept Corporation announces the release of new findings demonstrating the pharmacoeconomic benefits of Ceplene® (histamine dihydrochloride) for the remission maintenance of Acute Myeloid Leukemia (AML) patients in first remission.

26 Oct 2009

Cancer cells fueled by the mutant KRAS oncogene can be killed by blocking its genetic partner

Cancer cells fueled by the mutant KRAS oncogene, which makes them notoriously difficult to treat, can be killed by blocking a more vulnerable genetic partner of KRAS, report scientists at the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT.

26 Oct 2009

Research reveals that mutation of chromosome 16 increases risk of schizophrenia

An international team of researchers led by geneticist Jonathan Sebat, Ph.D., of Cold Spring Harbor Laboratory (CSHL), has identified a mutation on human chromosome 16 that substantially increases risk for schizophrenia.

26 Oct 2009

New urine tests may help predict kidney problems post surgery

Two studies presented at this week's Annual Meeting of the American Society of Anesthesiologists offer new information as to how physicians might better determine which surgical patients may be at risk for developing kidney injury after surgery.

26 Oct 2009

Wellcome Trust's 91M fund aims at developing new drugs related to the dengue fever virus

The Wellcome Trust spends over 600 million pounds each year to support its mission to foster and promote research with the aim to improving human and animal health. This funding supports basic research as well as technology transfer, the transfer of academic knowledge and technology to the corporate environment.

26 Oct 2009

Surgery offers hope for migraine sufferers

In newly released research, 79 migraine sufferers were followed for at least five years after having undergone detection of migraine "trigger sites" and surgery. The new data finds promising outcomes for treating trigger sites surgically for migraine headaches resulting in elimination of pain for those afflicted with the condition.

26 Oct 2009

Millions of children in the US suffer from suboptimal levels of vitamin D

Millions of children in the United States between the ages of 1 and 11 may suffer from suboptimal levels of vitamin D, according to a large nationally representative study published in the November 2009 issue of Pediatrics, accompanied by an editorial.

26 Oct 2009

Cancer News and Research

Latest Cancer News and Research

Ontario Lung Association partners with Health Canada for radon gas awareness campaign

Results from Phase I dose-escalation study of AT-101 announced

Rexahn Pharmaceuticals completes Registered Direct Offering of common stock and warrants

Cel Sci completes its production facility for Multikine Phase III clinical trial

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

Overview of Compugen’s DAC Blockers Platform presented at Fifth Peptide Engineering Meeting

SuperGen and GSK team up to discover and develop cancer therapeutics based on epigenetic targets

Canadian cardiologists, oncologists team up to fight breast cancer

Younger women experience larger improvements after myocardial infarction than men

Japanese Patent granted for Pharmalink AB's Nefecon

Novel protein responsible for changing DNA structure and silencing the expression of genes identified

Potential link exists between histone mRNA formation and apoptosis

USPTO reaffirms the validity of ExonHit Therapeutics' SpliceArray patent

New findings demonstrating pharmacoeconomic benefits of Ceplene released

Cancer cells fueled by the mutant KRAS oncogene can be killed by blocking its genetic partner

Research reveals that mutation of chromosome 16 increases risk of schizophrenia

New urine tests may help predict kidney problems post surgery

Wellcome Trust's 91M fund aims at developing new drugs related to the dengue fever virus

Surgery offers hope for migraine sufferers

Millions of children in the US suffer from suboptimal levels of vitamin D

Industry Focus: Cell & Gene Therapy eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Cancer News and Research

Latest Cancer News and Research

Industry Focus: Cell & Gene Therapy eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in